» Articles » PMID: 33259778

Prevalence, Clinical Features and Prognosis of Malignant Solid Tumors in Infants: a 14-year Study

Overview
Specialty General Medicine
Date 2020 Dec 1
PMID 33259778
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

The onset of malignant solid tumors in infants is insidious and difficult to diagnose on time. The purpose of our study is to provide a theoretical basis for clinical diagnosis by retrospective analysis of the data in the past 14 years. Here, we retrospectively collected the clinical data of infants aged 0-12 months with malignant solid tumors in Beijing Tongren Hospital Affiliated to Capital Medical University from May 2005 to May 2019. The epidemiology, clinical characteristics, treatments and prognosis were statistically analyzed. A total of 496 infants (294 males and 202 females) with malignant solid tumors were analyzed. The main period of onset was 1-11 months. The most common tumor was retinoblastoma (RB, 51.8%), followed by hepatoblastoma (HB, 26.6%), neuroblastoma (NB, 10.5%), rhabdomyosarcoma (RMS, 3.4%), malignant renal tumors (3.2%), infantile fibrosarcoma (IFS, 1.6%), malignant teratoma (1.2%), Ewing's sarcoma (ES, 0.8%), medulloblastoma (MB, 0.4%) and inflammatory myofibroblastic tumor (IMT, 0.4%). The median follow-up time was 32 months (range 2-162 months). The 1-year, 3-year, and 5-year overall survival of all patients were 97.3%, 89.2%, and 81.1%, respectively, and event-free survival was 94.7%, 84.8%, and 75.8%, respectively. In conclusion, as a special group, malignant solid tumors in infants are complex, heterogeneous, and relatively rare. The prognosis of RB, HB, NB, RMS, malignant renal tumors, IFS, malignant teratoma, ES, MB, and IMT, were excellent duo to timely diagnosis and rational treatment.

Citing Articles

Rhabdomyosarcoma or Fibrosarcoma? A Case of Large Ulcerated and Necrotic Lesion on the Forearm of a Newborn.

Soqia J, Aloqla N, Janoud O, Al-Shafie M, Nader M J Investig Med High Impact Case Rep. 2023; 11:23247096231209541.

PMID: 37919979 PMC: 10623988. DOI: 10.1177/23247096231209541.


LncRNA SNHG1 Accelerates Cell Proliferation, Migration, and Invasion of Hepatoblastoma Through Mediating miR-6838-5p/PIM3/RhoA Axis.

Zhang T, Ji C, Zhang Y, Yuan M, Gao H, Yin Q Biochem Genet. 2023; 62(1):59-76.

PMID: 37248373 DOI: 10.1007/s10528-023-10404-x.

References
1.
Ferrari A, De Salvo G, Brennan B, van Noesel M, De Paoli A, Casanova M . Synovial sarcoma in children and adolescents: the European Pediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005). Ann Oncol. 2014; 26(3):567-72. DOI: 10.1093/annonc/mdu562. View

2.
Bhakta N, Force L, Allemani C, Atun R, Bray F, Coleman M . Childhood cancer burden: a review of global estimates. Lancet Oncol. 2019; 20(1):e42-e53. DOI: 10.1016/S1470-2045(18)30761-7. View

3.
Naranjo A, Irwin M, Hogarty M, Cohn S, Park J, London W . Statistical Framework in Support of a Revised Children's Oncology Group Neuroblastoma Risk Classification System. JCO Clin Cancer Inform. 2019; 2:1-15. PMC: 6421832. DOI: 10.1200/CCI.17.00140. View

4.
Ranganathan S, Lopez-Terrada D, Alaggio R . Hepatoblastoma and Pediatric Hepatocellular Carcinoma: An Update. Pediatr Dev Pathol. 2019; 23(2):79-95. DOI: 10.1177/1093526619875228. View

5.
Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H . Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A. 2004; 101(38):13885-90. PMC: 518848. DOI: 10.1073/pnas.0405884101. View